|
|
|
| Efficacy comparation of ergostine combined with hemabate or oxytocin for treating postpartum hemorrhage |
| Chaoyang District Maternal and Child Health Care Hospital, Beijing, 100021 |
|
|
|
Abstract To study the efficacy comparation of ergostine combined with hemabate or oxytocin for treating postpartum hemorrhage. Methods: A total of 208 women with postpartum hemorrhage were selected as the research objects from June 2021 to June 2022. According to the different treatment methods, these women were divided into observation group (124 cases with treatment of ergostine combined with hemabate) and control group (84 cases with treatment of ergostine combined with oxytocin). The blood loss at 2 hours, 12 hours, or 24 hours after treatment of the women was compared between the two groups. The coagulation function, the uterine recovery, and the adverse reactions of the women were compared between the two groups. The prognostic factors of the women in the two groups were analyzed. Results: The blood loss in 2h (218.57±35.49 ml), 12h (239.59±81.47 ml), and 24h (265.72±55.73ml) after treatment, and the duration of bleeding (32.68±4.64d) of the women in the observation group were significantly lower than those (236.38±36.68 ml, 286.59±83.68 ml, 389.59±56.47 ml, and 43.38±6.68d) of the women in the control group. The values of coagulation function indexes, such as fibrinogen (2.36±0.53) and activated partial thrombin time (28.59±3.49s) of the women in the observation group were significantly lower than those (3.86±0.56 and 29.98±4.29s) of the women in the control group. The contraction amplitude (236.60±124.29 mm), contraction strength (1524.68±220.42 mm), and contraction tension (1429.69±225.70 mm) of uterus of the women in the observation group were significantly lower than those (428.58±124.31 mm, 1769.52±223.16 mm, and 1589.32±129.68 mm) of the women in the control group. The frequency of contractions (1-2 times /min) of uterus of the women in the observation group was significantly higher than that (1 time /min) of the women in the control group (all P＜0.05). The factors influencing the number of complications of the women included treatment methods, delivery mode, cause
of bleeding, age, body mass index, duration of treatment, volume of bleeding in 12h after treatment, duration of bleeding, uterine tension, and D-dimer level. Conclusion: Ergostine combined with hemabate for treating postpartum hemorrhage of the women has higher effective, which can reduce bleeding, promote uterine recovery, accelerate coagulation, and reduce the incidence of complications.
|
|
|
|
|
|
|
|
|
